Executive Scott Storrer possesses more than a decade of leadership experience in the health and science fields. Currently serving as the president of the North America division at Strand Life Sciences, Scott Storrer formerly founded and led Genomind as its president and CEO for nearly four years.

2. Executive Scott Storrer possesses more than a
decade of leadership experience in the health and
science fields. Currently serving as the president of
the North America division at Strand Life Sciences,
Scott Storrer formerly founded and led Genomind
as its president and CEO for nearly four years.
In March 2014, Genomind and ValueOptions joined
together to research pharmacogenomic testing
used in treating patients who suffer from bipolar
disorder, schizophrenia, and other psychotic
disorders.

3. The study, hosted at the North Shore-LIJ Health
System’s Zucker Hillside Hospital, integrates
Genomind’s Genecept Assay and works toward
identifying key factors that impact treatment
decisions and resource use. In addition,
researchers look to evaluate behavior changes
following pharmacogenomic testing and the
treatment’s effectiveness.

4. Biomarkers are used during the clinical study to
take readings and translate the data. By using
this tool, researchers can gather specific details
on whether or not pharmacogenomic testing
can be customized to a patient’s genetic and
biological needs.
Visit www.genomind.com to learn more about
the study.